Dongbao Biotech (300239): Gelatin and by-products business grew steadily, Yiqing Biotech added a new capsule production capacity of 15 billion capsules/year
Dongbao Biotech (300239): Net profit from mother in the first three quarters increased by +9% compared to the same period, gross margin increased by nearly 1PCT
Dongbao Biotech (300239): 23H1 Gimu's net profit was +12.12% year-on-year, continuing to promote industrial chain integration
Dongbao Biotech (300239): Net profit increased significantly by +31% compared to the same period in Q1
Dongbao Biotech (300239): Guimu's net profit is +200% year-on-year, expanding new fields of application of gelatin and collagen products
Toho Biotech (300239): Profitability continues to improve, Q3 returns net profit increased 381%
Dongbao Biotech (300239): The company's operating efficiency increased significantly, 22H1 net profit increased 668%, gross margin increased 14PCT
Dongbao Biotech (300239) Company Dynamic Review: Return to Mother's Net Profit Increased 98% Year-on-Year in '21 to Build a Leading Domestic Collagen Brand
Dongbao Bio (300239): 21 years' net profit growth of 93%. Profitability rebounded significantly.
Dongbao Bio (300239): forecast full-year return net profit 3000-40 million profitability rebounded significantly
Dongbao Biological (300239): equity incentive plan brings together people, new production capacity, new products and new growth.
Dongbao Biotech (300239): After implementing the employee stock ownership plan, graduation records reached an inflection point this year
[Changjiang Securities] Dongbao Biology: aim high, "Yuansu" is worth looking forward to
Dongbao Biological (300239) performance Forecast comment: raise the price of gelatin in full production of the fund-raising project
[Rixin Securities] Dongbao Bio: the fund-raising project has been fully put into production, and the price of gelatin has increased.
[Rixin Securities] Dongbao Biological Review: the degree of industry integration is high, and the performance will be gradually improved.
[Shanghai Securities] Dongbao Biological depth report: the prosperity of gelatin business is improving, and there are many bright spots of collagen.
[Rixin Securities] Dongbao Bio: the performance is in line with expectations, waiting for the collagen breakthrough.
[Nippon Securities] Dongbao Bio: performance meets expectations, collagen improves performance
【日信证券】东宝生物调研简报:明胶稳定增长,胶原蛋白蓄势待发
No Data